Trials / Active Not Recruiting
Active Not RecruitingNCT06466187
A Study of SGN-MesoC2 in Advanced Solid Tumors
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Ovarian Neoplasms
- Pancreatic Adenocarcinoma
- Colorectal Neoplasms
- Mesothelioma
- Other Solid Tumors
- Endometrial
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-08052666 | Given into the vein (IV; intravenously) |
Timeline
- Start date
- 2024-08-02
- Primary completion
- 2028-05-01
- Completion
- 2029-05-01
- First posted
- 2024-06-20
- Last updated
- 2026-01-12
Locations
21 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06466187. Inclusion in this directory is not an endorsement.